Percheron Therapeutics Limited PER

London, United Kingdom--(Newsfile Corp. - September 4, 2026) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron's clinical strategy has taken an important turn with the announcement of an investigator-sponsored exploratory study of HMBD-002 in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), led by Vanderbilt Health. Percheron's contribution will be limited to providing the study drug, a financial grant and advisory support. Following the announcement, the...

Cancer immunotherapy has reshaped the oncology landscape over the past decade, but the next phase of development is increasingly focused on finding new immune checkpoints that can extend the benefits of existing treatments to patients who either do not respond or eventually relapse. That...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured firm commitments for a $2.3 million institutional placement, providing full funding for its newly announced clinical trial of lead oncology candidate HMBD-002 in acute myeloid leukaemia (AML) and myelodysplastic syndrome...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has received a $700,000 Research and Development Tax Incentive rebate for the 2026 financial year, providing additional funding for the clinical development of its lead oncology asset HMBD-002. The rebate relates to eligible research and...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has entered a clinical research agreement with Vanderbilt Health in the US for a new multi-centre trial of its lead cancer therapy HMBD-002 in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). The investigator-sponsored study...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has appointed experienced biotechnology executive Dr Michael Baker as managing director and chief executive officer, with the leadership change coming as the company prepares to advance its lead oncology asset, HMBD-002, into a new clinical trial...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) (Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF)) remains on track to begin a Phase II trial of HMBD-002 in the fourth quarter of 2026, according to Edison Investment Research, which has maintained its A$84.4 million valuation, equivalent to 5.5...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) advanced preparations to return its lead cancer drug HMBD-002 to the clinic during the June 2026 quarter, completing manufacture of a new drug substance batch, raising $2.2 million and presenting supporting data at two major international oncology...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has appointed Dr Charmaine Gittleson and Michael Kotsanis as non-executive directors as part of a board enhancement process aimed at supporting the company’s clinical-stage cell therapy strategy. Both appointments take effect from June 30,...

Insiders who acquired AU$157.7k worth of Percheron Therapeutics Limited's ( ASX:PER ) stock at an average price of...